

Press Release

Daiichi Sankyo Announces Appointment of Chief Corporate Affairs Officer under the Global Management Structure

Tokyo, Japan - (April 16, 2026) – Daiichi Sankyo Company, Limited today announced the appointment of Chief Corporate Affairs Officer under the Global Management Structure effective from April 16, 2026.

Global Corporate Function

Name	Current Responsibilities*	New Responsibilities*
Takashi Matsumoto	Head of Global HR Chief Human Resources Officer (CHRO)	Head of Global HR Chief Human Resources Officer (CHRO) Head of Global Corporate Affairs Chief Corporate Affairs Officer (CCAO)

* Responsibilities as CxO, Head of Global Corporate Function or Unit Head etc. under the current Global Management Structure

CEO

Name	Responsibilities*
Hiroyuki Okuzawa	Chief Executive Officer (CEO)

Global Corporate Function

Name	Responsibilities*
Nobuo Murakami	Head of Global Corporate Strategy Chief Strategy Officer (CStO)
Stuart Mackey	Head of Global Business Development
Tomohiro Kodama	Head of Global Corporate Planning & Management Chief Financial Officer (CFO)
James Felix	Head of Global DX Chief Digital Transformation Officer (CDXO)
Takashi Matsumoto	Head of Global HR Chief Human Resources Officer (CHRO) Head of Global Corporate Affairs Chief Corporate Affairs Officer (CCAO)
Naoto Tsukaguchi	Head of Global Legal & IP General Counsel (GC)
Matt Allegrucci	Head of Global Compliance & Risk Management Chief Compliance Officer (CCO)
Naoki Shimizu	Head of Global QA Chief Quality Officer (CQO)

Business Units

Name	Responsibilities*
Shizuko Ueno	Head of Japan Business Unit
Ken Keller	Head of Oncology Business Unit
Oliver Appelhans	Head of EU Specialty Business Unit
Yuichi Yomasu	Head of ASCA Business Unit
Paul Diolosa	Head of American Regent Unit
Takahiro Uchida	Head of Daiichi Sankyo Healthcare Unit

Functional Units

Name	Responsibilities*
John Tsai	Head of Research & Development Unit
Koji Sato	Head of Technology Unit
Kento Wada	Head of Clinical Safety & Pharmacovigilance Unit

Global Oncology Business

Name	Responsibilities*
Ken Keller ⁴	Head of Global Oncology Business

Business Transformation

Name	Responsibilities*
Tetsuya Ohira	Head of Business Transformation Chief Business Transformation Officer (CTO)

CEO Chief of Staff Office

Name	Responsibilities*
Satoru Ogawa	Head of CEO Chief of Staff Office

Internal Audit

Name	Responsibilities*
Manabu Murata	Head of Global Internal Audit

Special Assignment

Name	Responsibilities*
Koji Ogawa	Dean, DS Academy
Shizuko Ueno	Special Assignment on Patient Centricity

* Responsibilities as CxO, Head of Global Corporate Function or Unit Head etc. under the current Global Management Structure

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the

world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.

Contacts:

Media Contact (Japan):

Daiichi Sankyo Co., Ltd.

DS-PR_jp@daiichisankyo.com

Investor Relations Contact:

DaiichiSankyoIR_jp@daiichisankyo.com